# US 2008/0287362 A1 · Compositions and Methods for the Detection of Trypanosoma Cruzi Infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287362 A1
- Document ID: US20080287362A1
- Status: Published application
- Kind: A1
- Application number: 12/092,562
- Filed: 2006-11-02
- Published: 2008-11-20
- Earliest claimed: 2005-11-03
- Assignees: InBios International, Inc.; Infectious Disease Research Institute
- Inventors: Raymond L. Houghton; Steven G. Reed; Syamal Raychaudhuri
- Web page: https://patentgrep.com/patent/US20080287362A1

## CPC

- C07K 14/44: from protozoa
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- G01N 2333/44: from protozoa
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10S 435/975: Kit
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Compositions comprising fusion polypeptides of T. cruzi epitopes are provided, together with methods for the use of such compositions in the diagnosis of T. cruzi infection and in screening blood supplies. Diagnostic kits comprising such compositions are also provided.

## Claims

### Claim at position 1

1: A fusion polypeptide comprising an amino acid sequence of SEQ ID NO: 1 and at least one amino acid sequence selected from the group consisting of: SEQ ID NO: 2-7.

### Claim at position 2 (depends on 1)

2: The fusion polypeptide of claim 1, wherein the fusion polypeptide comprises the amino acid sequences of SEQ ID NO: 1, 2, 3 and 4.

### Claim at position 3 (depends on 1)

3: The fusion polypeptide of claim 1, wherein the fusion polypeptide comprises the amino acid sequences of SEQ ID NO: 1, 2, 3, 4 and 5.

### Claim at position 4 (depends on 1)

4: The fusion polypeptide of claim 1, wherein the fusion polypeptide comprises the amino acid sequences of SEQ ID NO: 1, 2, 3, 4, 5 and 6.

### Claim at position 5 (depends on 1)

5: The fusion polypeptide of claim 1, wherein the fusion polypeptide comprises the amino acid sequences of SEQ ID NO: 1, 2, 3, 4, 5 and 7.

### Claim at position 6 (depends on 1)

6: The fusion polypeptide of claim 1, wherein the fusion polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 8, 15, 17, 19, and 20.

### Claim at position 7

7: A fusion polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) sequences having at least 85% identity to SEQ ID NO: 8, 15, 17, 19 or 20;
(b) sequences having at least 90% identity to SEQ ID NO: 8, 15, 17, 19 or 20; and
(c) sequences having at least 95% identity to SEQ ID NO: 8, 15, 17, 19 or 20,
wherein the fusion polypeptide is capable of generating at least 80% of the response generated by a fusion polypeptide of SEQ ID NO: 8, 15, 17, 19 or 20 to T. cruzi-infected sera in an antibody binding assay.

### Claim at position 8 (depends on 1)

8: An isolated polynucleotide sequence encoding a fusion polypeptide according to claim 1.

### Claim at position 9 (depends on 8)

9: A recombinant expression vector comprising a polynucleotide sequence according to claim 8.

### Claim at position 10 (depends on 9)

10: A host cell transformed or transfected with an expression vector according to claim 9.

### Claim at position 11 (depends on 1)

11: A method for detecting T. cruzi infection in a biological sample, comprising:
(a) contacting the biological sample with a fusion polypeptide of claim 1; and
(b) detecting in the biological sample the presence of antibodies that bind to the fusion polypeptide, thereby detecting T. cruzi infection in the biological sample.

### Claim at position 12 (depends on 11)

12: The method of claim 11, wherein the biological sample is selected from the group consisting of: blood, serum, plasma, saliva, cerebrospinal fluid and urine.

### Claim at position 13 (depends on 1)

13: A diagnostic kit for detecting T. cruzi infection in a biological sample, comprising:
(a) a fusion polypeptide of claim 1; and
(b) a detection reagent.

### Claim at position 14 (depends on 13)

14: The kit of claim 13, wherein the detection reagent comprises a reporter group.

### Claim at position 15 (depends on 14)

15: The kit of claim 14, wherein the reporter group is selected from the group consisting of: enzymes, substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups, and biotin.

### Claim at position 16 (depends on 1)

16: A composition comprising a fusion protein according to claim 1 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

### Claim at position 17 (depends on 16)

17: A method for the prevention or treatment of T. cruzi infection in a patient, comprising administering to the patient a composition of claim 16.

### Claim at position 18

18: A method for detecting T. cruzi infection in a biological sample, comprising:
(a) contacting the biological sample with a fusion polypeptide of SEQ ID NO: 19; and
(b) detecting in the biological sample the presence of antibodies that bind to the fusion polypeptide, thereby detecting T. cruzi infection in the biological sample.

### Claim at position 19

19: A diagnostic kit for detecting T. cruzi infection in a biological sample, comprising:
(a) a fusion polypeptide of SEQ ID NO: 19; and
(b) a detection reagent.

### Claim at position 20

20: A composition comprising a fusion protein of SEQ ID NO: 19 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.
